Skip to main content

Table 1 Associations of membranous ezrin expression with clinicopathological and investigative parameters in two independent patient cohorts of urothelial bladder cancer

From: Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts

  

Cohort I (n = 100)

 

Cohort II (n = 342)

Factor

n (%)

Ezrin expression

 

n (%)

Ezrin expression

 
  

median (range)

p-value

 

median (range)

p-value

Age

      

≤ average

46 (46.9)

30.9 (0.0-100)

0.222

157 (45.9)

10.0 (0.0-100)

0.136

>average

54 (54.0)

35.0 (0.0-95.0)

 

185 (54.1)

10.0 (0.0-100)

 

Gender

      

Female

25 (25.9)

10.0 (0.0-90.0)

0.040

82 (24.0)

5.00 (0.0-90.0)

0.013

Male

75 (75.0)

40.0 (0.0-100)

 

260 (76.0)

10.0 (0.0-100)

 

T-stage

      

Ta

41 (41.0)

75.0 (0.0-100)

<0.001

115 (33.6)

30.0 (0.0-100)

<0.001

T1

22 (22.0)

25.0 (0.0-95.0)

 

116 (33.9)

10.0 (0.0-95.0)

 

T2-3

37 (37.0)

2.0 (0.0-80.0)

 

111 (32.5)

0.0 (0.0-60.0)

 

Grade

      

Low

44 (44.0)

72.5 (0.0-100)

<0.001

82 (24.0)

40.0 (0.0-100)

<0.001

High

56 (56.0)

10.0 (0.0-90.0)

 

260 (76.0)

5.0 (0.0-95.0)

 

PODXL expression

      

Negative

78 (78.8)

40.0 (0.0-100)

<0.001

306 (89.7)

10.0 (0.0-100)

0.009

Positive

21 (21.0)

5.00 (0–70.0)

 

35 (10.2)

(0.0-0.80)